Memorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

• Target Audience: general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers
• Sample video: contact me for sample video
• Information:

Specialties – Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine

Overview

This one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q&A.

Now in its 10th year, the 2025 program will focus on:

Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)

Advances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders

Hematologic complications related to cellular therapies and immunotherapies

Novel treatment approaches, including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use

The target audience for this symposium includes general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered exclusively in person; a virtual attendance option will not be available.

Following the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.

Objectives

At the conclusion of this symposium, attendees will be able to:

Discuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics

Analyze current data and discuss emerging FXI inhibitors

Describe anticomplement therapies

Recognize the challenges in diagnosis and management of hematologic complications of immunotherapy

• Topics:

Sunday, October 26, 2025

Emerging Data on Factor XI Inhibitors

Jeffrey Zwicker, MD

Cryptogenic Stroke and Cancer

Babak Navi, MD

Benefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery

Marc Carrier, MD

Thrombotic Risk in Acute Lymphoblastic Leukemia

Avi Leader, MD

Inherited Hemolytic Anemias: Scientific Advances in Therapeutics

Mohandas Narla, DSc

Anticomplement Therapy for Paroxysmal Nocturnal Hemoglobinuria

david araten, MD

Management of Cold Agglutinin Disease

Rekha Parameswaran, MD

HLH-like Toxicities Secondary to Cancer Immunotherapy

William Johnson, DO

Thrombosis Related to Immune Therapy

Jodi Mones, MD

Updates in Immune Thrombocytopenia

Cy R Wilkins, MD

Transplant-Associated Thrombotic Microangiopathy

Mohammad Alhomoud, MBBS